FOUNDATIONONE®CDx

PATIENT
redacted

TUMOR TYPE
Ovary serous carcinoma
COUNTRY CODE
redacted

REPORT DATE
Invalid date
TST#
000000

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Ovary serous carcinoma
NAME redacted
DATE OF BIRTH Not Given
SEX redacted
MEDICAL RECORD # redacted

PHYSICIAN

ORDERING PHYSICIAN redacted
MEDICAL FACILITY redacted
ADDITIONAL RECIPIENT redacted
MEDICAL FACILITY ID redacted
PATHOLOGIST redacted

SPECIMEN

SPECIMEN SITE redacted
SPECIMEN ID redacted
SPECIMEN TYPE Block
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

Biomarker Findings

Loss of Heterozygosity score - 21.1 %
Microsatellite status - MS-Stable
Tumor Mutational Burden - 6 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

BRCA1 Q1756fs*74
PDGFRB amplification - equivocal†
TP53 R273C
FGF12 amplification - equivocal†

1 Disease relevant genes with no reportable alterations: ***BRCA2***

† See About the Test in appendix for details.

6 Therapies with Clinical Benefit
0 Therapies with Lack of Response
15 Clinical Trials

BIOMARKER FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
Loss of Heterozygosity score - 21.1 %	Niraparib 2A	Talazoparib
	Olaparib 2A	
10 Trials *see p. 11*	Rucaparib 2A	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 6 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	

GENOMIC FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
***BRCA1* -** Q1756fs*74	Olaparib 1	Talazoparib
	Niraparib 2A	
10 Trials *see p. 14*	Rucaparib 2A	
***PDGFRB* -** amplification - equivocal	none	Sorafenib 2A
2 Trials *see p. 17*		Sunitinib
***TP53* -** R273C	none	none
1 Trial *see p. 18*		

☐ *NCCN category (resistance may not be reflected in NCCN category)*

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

FGF12 - amplification - equivocal ..... p. 6

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

BIOMARKER

Loss of Heterozygosity score

RESULT
21.1 %

POTENTIAL TREATMENT STRATEGIES

On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors[1-2]. In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score ≥ 16%[2]. In the maintenance setting in platinum-sensitive, BRCA1/2 wild-type patients, rucaparib was superior to placebo in both the LOH score ≥ 16% (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score < 16% (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts[1]. Similar results have been reported for maintenance treatment with niraparib in ovarian cancer[3] when using a different measure of HRD that includes genomic LOH[4-5]. Increased LOH has also been associated with improved sensitivity to platinum-containing chemotherapy regimens in patients with ovarian or breast cancer[6-8].

FREQUENCY & PROGNOSIS

In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score ≥ 16% was identified in 24.2% of BRCA1/2 wild-type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score < 16% and were BRCA1/2 wild-type[9]. Among the histological subtypes, LOH score ≥ 16% or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild-type samples, the median LOH score was significantly higher in serous as compared with non-serous cases[9]. In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2-mutated cases than BRCA1/2 wild-type cases (22.2% vs. 9.8%)[9], and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with increased genomic LOH[6,10]. One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma[11]. In patients with high-grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age[12].

FINDING SUMMARY

The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele[2]; focal LOH events accumulate as genomic "scars" as a result of incorrect DNA double-strand break repair when the homologous recombination pathway is deficient (HRD)[6,10,13-14]. HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1[13-16]. This sample harbors a genomic LOH score that has been shown to be associated with sensitivity to the PARP inhibitor rucaparib in platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma in both the treatment[2] and maintenance[1] settings.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[17-19], including approved therapies nivolumab and pembrolizumab[20]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[21].

FREQUENCY & PROGNOSIS

MSI-high (MSI-H) has been reported in 1.6-19.7% of ovarian cancer samples[22-23], including 3.8% (1/26) of ovarian endometrioid adenocarcinomas[24], 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs)[25] and 84.6% (11/13) of ovarian cystadenocarcinomas[26]. MSI-H was also frequently observed in ovarian cystadenomas (60.0%; 6/10) and normal ovary tissue (78.6%; 11/14)[26]. No association of MSI-H with stage or survival was found in patients with ovarian cancer[22,27].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[28]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[28-30]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[31-33]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[28,30,32-33].

BIOMARKER

Tumor Mutational Burden

RESULT
6 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[34-36] and anti-PD-1 therapies[34-37]. Higher TMB has corresponded with increased ORR and OS from treatment with immune checkpoint inhibitors in pan-tumor studies[34-37]. Analyses across several solid tumor types have identified that patients with higher TMBs (≥16-20 Muts/Mb) achieved greater clinical benefit using PD-1/PD-L1 monotherapy, compared with patients treated with chemotherapy[38] or those with lower TMBs[35]. Additionally, higher TMB is significantly associated with improved OS with immune checkpoint inhibitor treatment for patients with advanced cancer across 9 solid tumor types[34]. However, the KEYNOTE 158 trial found significant improvement in ORR in a large cohort of patients with a TMB of ≥10 Muts/Mb compared with those with TMBs <10 across multiple solid tumor types, with similar findings observed in the KEYNOTE 028 and 012 trials[37]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1/PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Ovarian carcinomas, including peritoneal and Fallopian tube carcinomas, harbor a median TMB of 2.7-3.6 mutations per megabase (muts/Mb) depending upon subtype, and up to 2.1% of cases have high TMB (>20 muts/Mb)[39]. In a study of high grade serous ovarian cancer, homologous recombination (HR)-deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR-proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival[40].

FINDING SUMMARY

Tumor mutational burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[41-42] and cigarette smoke in lung cancer[43-44], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[45-49], and microsatellite instability (MSI)[45,48-49]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[35-36].

GENE
BRCA1

ALTERATION
Q1756fs*74

TRANSCRIPT NUMBER
NM_007294

CODING SEQUENCE EFFECT
5266_5267insC

POTENTIAL TREATMENT STRATEGIES

Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors[2-3,50-64]. Clinical response to PARP inhibitors has been reported for patients with either germline or somatic BRCA2 mutations[2,51,57,64] and for patients who were platinum-resistant or refractory[50,54,60,63]. The placebo-controlled Phase 3 VELIA trial reported significantly improved median PFS for previously untreated patients with high-grade serous ovarian carcinoma treated with veliparib plus carboplatin-paclitaxel chemotherapy followed by single-agent veliparib maintenance therapy relative to carboplatin-paclitaxel induction without maintenance therapy for BRCA-mutated (34.7 vs. 22.0 months, HR=0.44) and homologous-recombination deficient (HRD; 31.9 vs. 20.5 months, HR=0.57) populations[65]. In this study, the addition of veliparib to chemotherapy induction without veliparib maintenance did not improve median PFS (21.1 vs. 22.0 months) relative to chemotherapy induction in the BRCA-mutated (21.1 vs. 22.0 months, HR=1.22) or HRD (18.2 vs. 20.5 months, HR=1.10) cohorts[65]. In a Phase 1 monotherapy trial of the WEE1 inhibitor adavosertib that included 9 patients with BRCA1/2-mutated solid tumors, 2 patients with BRCA1-mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with an ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression[66].

FREQUENCY & PROGNOSIS

In the Ovarian Serous Cystadenocarcinoma TCGA dataset, BRCA1 mutation was detected in 11.4% of cases while putative homozygous deletion of BRCA1 was found in fewer than 1% of cases[15]. An analysis of ovarian tumors showed that BRCA1 alterations (including mutations, LOH, and promoter methylation) occurred in 77.6% of tumors; mutations and LOH were associated with advanced stage and concurrent TP53 mutations[67-68]. BRCA1 hypermethylation has been correlated with BRCA1 protein loss, and has been identified as a contributing factor to ovarian cancer progression[67,69]. BRCA1 mutations occur more frequently in advanced stage ovarian tumors, but also are associated with longer overall survival and with increased response to chemotherapy in patients with ovarian cancer[67,70-74]. Approximately 15% of ovarian cancers are familial; in BRCA1 or BRCA2 carriers, tumors are more likely to be Type 2 high-grade tumors[75].

FINDING SUMMARY

The protein encoded by BRCA1 is involved in the maintenance of genomic stability, including DNA repair, cell cycle checkpoint, and chromosome segregation[76]. BRCA1 alterations that disrupt the ring-type zinc finger domain (amino acids 24-65) or BRCT domains (aa 1642-1855), such as observed here, are predicted to result in a loss of function[77-79]. The alteration seen here is one of several BRCA1/2 founder mutations seen with disproportionately high frequency in the Ashkenazi Jewish population. The most common Ashkenazi founder mutations are BRCA1 185delAG (E23fs*17), BRCA1 5382insC (Q1756fs*74), and BRCA2 6174delT (S1982fs*22). Germline mutations in BRCA1 or BRCA2 are associated with breast-ovarian cancer familial susceptibility (BROVCA), also known as hereditary breast-ovarian cancer (HBOC)[80-81]. The lifetime risk of breast and ovarian cancer in BRCA1/2 mutation carriers has been estimated to be as high as 87% and 44%, respectively[82], and elevated risk of other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, at a frequency range of 20-60%[83]. The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10-fold higher prevalence in the Ashkenazi Jewish population[82,84-89]. In the appropriate clinical context, germline testing of BRCA1 is recommended.

GENE
PDGFRB

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical benefit for patients with renal cell carcinoma[90-93] or solitary fibrous tumor[94-95], as well as for a patient with urothelial carcinoma[96] and a patient with clear cell sarcoma[97], PDGFRB expression is associated with sensitivity to sorafenib and sunitinib. Significant clinical benefit has also been achieved with dasatinib or imatinib in PDGFRB fusion-positive acute lymphoblastic leukemia[98-101], chronic eosinophilic leukemia[102-104], and various other hematologic malignancies[105-109].

FREQUENCY & PROGNOSIS

PDGFRB expression has primarily been studied in ovarian subtypes of serous carcinoma. PDGFRB amplification or mutation have each been reported 0-1% of ovarian serous carcinoma cases (COSMIC, Oct 2019)[15]. One study showed that PDGF and PDGFRB were expressed in 10/10 and 8/10 patient-derived samples of high-grade serous ovarian cancer, respectively[110]. In another study, PDGFRB was expressed in 81% of serous ovarian carcinomas and was more frequently found in high-grade tumors; however, expression was also detected in 93% of samples of normal ovarian epithelium[111]. The prognostic significance of PDGFRB alteration in ovarian cancer has not been extensively studied (PubMed, Oct 2019).

FINDING SUMMARY

PDGFRB (Platelet-derived growth factor receptor, beta) encodes PDGFR-beta, a receptor tyrosine kinase that binds growth factors of the platelet-derived growth factor (PDGF) family. It is located on chromosome 5q33, and rearrangements involving this gene that result in its constitutive activation have been found in chronic myeloproliferative diseases[105,112-115]. PDGFRB copy number gain correlates positively with higher PDGFR-beta protein expression[116].

GENE
TP53

ALTERATION
R273C

TRANSCRIPT NUMBER
NM_000546

CODING SEQUENCE EFFECT
817C>T

POTENTIAL TREATMENT STRATEGIES

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[117-120], or p53 gene therapy and immunotherapeutics such as SGT-53[121-125] and ALT-801[126]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutant p53 such as APR-246[127-129]. In a Phase 1b trial in patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[130]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 10% (17/176) and SDs in 53% (94/176) of patients with solid tumors; the response rate was 21% (4/19) in patients with TP53 mutations versus 12% (4/33) in patients who were TP53 wild-type[131]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR in patients with platinum refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[132]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR in patients with platinum-refractory TP53-mutated ovarian cancer[133]. The combination of adavosertib with paclitaxel and carboplatin in patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[134]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate in patients with TP53 alterations[135]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel in patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[125]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutant, but not TP53-wild-type, breast cancer xenotransplant mouse model[136].

FREQUENCY & PROGNOSIS

TP53 alterations have been reported in 29-80% of ovarian tumors, with a higher incidence in high-grade pelvic (primary ovarian, tubal, or peritoneal) serous carcinoma, with incidence of 91-97%[15,137-143]. TP53 alterations have also been reported in serous tubal intraepithelial carcinomas (STICs) of the Fallopian tube, which are suggested to be precursor lesions of tubo-ovarian high grade serous carcinomas[144-147]. Aberrant p53 expression has been associated with higher ovarian serous carcinoma grade (89-90% of high-grade vs. 6.6-9% of low-grade vs. 0% of benign)[148-150]. TP53 mutations have been reported to be more frequent in advanced stage (63%, 55/87) and higher grade (65%, 42/64) than earlier stage (31%, 14/45) and lower grade (41%, 7/17) ovarian carcinomas[142]. Meta-analysis has suggested that TP53 expression was associated with poorer survival in ovarian epithelial cancers, although the effect was modest and considerable variability was observed between studies[151].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[152]. Any alteration that results in the disruption or partial or complete loss of the region encoding the TP53 DNA-binding domain (DBD, aa 100-292) or the tetramerization domain (aa 325-356), such as observed here, is thought to dysregulate the transactivation of p53-dependent genes and is predicted to promote tumorigenesis[153-155]. Germline mutations in TP53 are associated with the very rare disorder Li-Fraumeni syndrome and the early onset of many cancers[156-158], including sarcomas[159-161]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[162] to 1:20,000[161]. In the appropriate clinical context, germline testing of TP53 is recommended.

GENE
FGF12

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

There are no therapies available to target alterations in FGF12.

FREQUENCY & PROGNOSIS

FGF12 mutations are rare (<1%) in cancer (COSMIC, 2019). However, FGF12 amplification has been reported in various tumors, with highest frequencies in lung squamous cell carcinoma (SCC) (27-39%), esophageal carcinoma (25%), ovarian serous cystadenocarcinoma (23%), and head and neck squamous cell carcinoma (HNSCC) (19%) (cBioPortal, 2019)[163]. FGF12 amplification was also reported in esophageal SCC in one study[164]. Hypermethylation of FGF12 promoter has been reported in a number of cancer types, including colorectal carcinoma[165], prostate cancer[166], non-small cell lung carcinoma (NSCLC)[167], endometrial carcinoma[168], and myeloid leukemia[169]. FGF12 expression was increased in diffuse type of gastric cancer[170], whereas it was downregulated in breast cancer samples from patients who had a pathological complete response (pCR) following chemotherapy[171].

FINDING SUMMARY

FGF12 is a member of the fibroblast growth factor (FGF) family. It does not activate any FGF receptors (FGFRs), and is not secreted from cells. Because it is expressed in developing as well as adult nervous systems, FGF12 is thought to be related to nervous system development and function[172].

Niraparib

Assay findings association

BRCA1
Q1756fs*74

Loss of Heterozygosity score
21.1 %

AREAS OF THERAPEUTIC USE

The PARP inhibitor niraparib is FDA approved for the maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is also approved to treat advanced ovarian, Fallopian tube, or primary peritoneal cancer with homologous recombination deficiency (HRD)-positive status after 3 or more prior lines of chemotherapy.

GENE ASSOCIATION

On the basis of clinical evidence in ovarian and breast cancers[3,54,173] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors[1-2,174] . In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16%[2,174] .

SUPPORTING DATA

In the maintenance setting for patients with ovarian, Fallopian tube, or primary peritoneal cancer, Phase 3 studies have shown niraparib to significantly increase median PFS (mPFS) relative to placebo[3,175] . The Phase 3 PRIMA trial reported significantly extended mPFS from niraparib maintenance therapy after response to first-line platinum chemotherapy for patients with newly-diagnosed ovarian cancer and homologous recombination-deficient (HRD) tumors (21.9 vs. 10.4 months; HR=0.43) and for the overall population (13.8 vs. 8.2 months; HR=0.62). For patients with HRD tumors, benefit was irrespective of BRCA status (BRCA-mutated, HR=0.40; BRCA wild-type, HR=0.50); patients with HR-proficient tumors also experienced PFS benefit (HR=0.68, p=0.02)[175]. The Phase 3 ENGOT-OV16/NOVA study showed niraparib maintenance therapy to significantly increase mPFS, compared to placebo, for patients with platinum-sensitive recurrent ovarian cancer and germline BRCA (gBRCA) mutations (21.0 vs. 5.5 months) and without gBRCA mutations (9.3 vs. 3.9 months), as well as for a patient subgroup without gBRCA mutations with HRD tumors (12.9 vs. 3.8 months)[3]. In a Phase 1 study of niraparib treatment for patients with solid tumors, 40.0% (8/20) of patients with ovarian cancer and BRCA mutations experienced a PR[54]. In the Phase 1/2 TOPACIO/KEYNOTE-162 study of niraparib in combination with pembrolizumab in patients with platinum-resistant ovarian cancer, the ORR was 18.3%, the DCR was 65.0% (3 CRs, 8 PRs, 28 SDs, 20 PDs), and mPFS was 3.4 months; no significant differences in efficacy were noted among analyzed subgroups (ORRs of 18.2% for patients with BRCA mutations vs. 19.1% for patients with BRCA wild-type tumors; 14.3% for patients with HRD-positive vs. 18.8 for patients with HRD-negative tumors; and 21.2% for patients with PD-L1-positive tumors vs. 9.5 for patients with PD-L1-negative tumors)[176]. A Phase 1 study of the combination of niraparib and bevacizumab for patients with platinum-sensitive, high-grade ovarian cancer reported a DCR of 90.9% (10/11), with a response rate of 45.5% (5/11)[177]. The follow-up Phase 2 trial comparing niraparib plus bevacizumab to niraparib alone found significant improvement in PFS with addition of bevacizumab (mPFS of 11.9 months for niraparib plus bevacizumab vs. 5.5 months for niraparib; HR=0.35; p<0.0001)[178].

Olaparib

Assay findings association

BRCA1
Q1756fs*74

Loss of Heterozygosity score
21.1 %

AREAS OF THERAPEUTIC USE

The PARP inhibitor olaparib is FDA approved to treat epithelial ovarian, Fallopian tube, or primary peritoneal cancer with or without a deleterious or suspected deleterious germline or somatic BRCA mutation under various treatment settings. Olaparib is also approved to treat patients with HER2-negative breast cancer and deleterious or suspected deleterious germline BRCA mutations who have had specific treatments. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on extensive clinical evidence in ovarian cancer[58-62] as well as strong clinical evidence in multiple other cancer types[50-52,58,61,179] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors[1-2,174] . In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16%[2,174] .

SUPPORTING DATA

Olaparib has been studied primarily for the treatment of ovarian cancer, and numerous studies have demonstrated significant clinical activity for patients with ovarian cancer harboring BRCA1/2 mutations, with response rates often significantly higher for patients with mutations than for those without[58,61] . For patients previously treated with chemotherapy, DCRs of 40-80% have been reported with olaparib, with response rates of up to 50%[58-63,180] . Two of three studies have shown significant correlation between platinum sensitivity and response to olaparib[60,63,179] . As first-line maintenance after CR or PR to prior platinum chemotherapy for patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer and a deleterious or suspected deleterious germline or somatic BRCA1/2 mutation, olaparib significantly improved 3-year PFS relative to placebo (60%, versus 27%, HR=0.30), with estimated median PFS not yet reached after 41 months of median follow up in a Phase 3 trial[64]. As maintenance therapy in the setting of relapsed disease, olaparib significantly improved median PFS (8.4 vs. 4.8 months) and OS (29.8 vs. 27.8 months) compared to placebo for patients with platinum-sensitive, high-grade serous ovarian cancer, with the greatest benefit observed for those individuals with BRCA1/2 mutations[57,181-182] . A placebo-controlled Phase 3 study for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer confirmed that olaparib maintenance therapy provides significant PFS benefit (19.1 vs. 5.5. months) for those who are BRCA-mutated and platinum-sensitive[56]. Combining olaparib with chemotherapy resulted in response rates up to 61%[179] and significantly longer PFS compared to chemotherapy alone[183] for patients with BRCA1/2-mutated ovarian cancer. Combining olaparib with the VEGFR inhibitor cediranib also increased the response rate and lengthened relapse-free survival for patients with platinum-sensitive ovarian cancer, compared to treatment with olaparib alone[184]. Clinical[185-186] and preclinical[187-188] studies have reported BRCA2 reversion mutations as a mechanism of olaparib resistance in ovarian cancer; similar resistance mechanisms have also been identified in prostate[189] and breast[190] cancers.

Rucaparib

Assay findings association

BRCA1
Q1756fs*74

Loss of Heterozygosity score
21.1 %

AREAS OF THERAPEUTIC USE

The PARP inhibitor rucaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations who have been previously treated with two or more chemotherapies. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

GENE ASSOCIATION

On the basis of strong clinical evidence in ovarian cancer[2,55,132] , as well as clinical data in other cancer types[55,191-192] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors[1-2,174] . In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16%[2,174] .

SUPPORTING DATA

In a Phase 3 study of rucaparib maintenance treatment for patients with platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or Fallopian tube carcinoma in response to platinum therapy, median PFS was significantly improved with rucaparib compared to placebo for patients with germline or somatic BRCA mutations (16.6 vs. 5.4 months, HR=0.23), patients with BRCA-mutated or BRCA wild-type and high loss of heterozygosity (LOH) tumors (collectively homologous recombination-deficient [HRD] tumors) (13.6 vs. 5.4 months, HR=0.32), and the overall population (10.8 vs. 5.4 months, HR=0.36), with CR rates of 18% (BRCA-mutated), 12% (HRD) and 7% (overall), and PFS benefit observed in the BRCA-wild-type and LOH-low group (HR=0.58)[1]. In a Phase 2 trial for patients with recurrent, platinum-sensitive ovarian, peritoneal, or Fallopian tube carcinoma, median PFS on rucaparib was significantly longer for patients with BRCA1/2 mutations (12.8 months) or high LOH (5.7 months) compared with patients with low LOH (5.2 months)[2]. Patients with high-grade ovarian carcinoma and deleterious BRCA mutations who had previously been treated with at least 2 chemotherapies achieved an ORR of 54% (9% CR, 45% PR) and a median duration of response of 9.2 months[2,193-194] . In a separate Phase 2 study of rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92.3% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously[55].

Sorafenib

Assay findings association

PDGFRB
amplification - equivocal

AREAS OF THERAPEUTIC USE

Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma.

GENE ASSOCIATION

On the basis of clinical responses for patients with PDGFRB-expressing renal cell carcinoma[93] and urothelial carcinoma[96], PDGFRB amplification in solid tumors may predict sensitivity to sorafenib.

SUPPORTING DATA

Multiple Phase 2 studies of sorafenib with or without paclitaxel/carboplatin for treatment of ovarian cancer have reported no or very limited efficacy and considerable toxicity[195-199] . However, a Phase 2 study of patients with ovarian cancer reported that addition of the topoisomerase inhibitor topotecan to sorafenib significantly improved progression-free survival (6.7 vs. 4.4 months) and overall survival (17.1 vs. 10.1 months) compared with addition of placebo; an altered dosing schedule also reduced adverse event frequency[200]. A case study of two patients with ovarian clear cell carcinoma treated with sorafenib reported stable disease with a duration of 6 months in both cases[201].

Sunitinib

Assay findings association

PDGFRB
amplification - equivocal

AREAS OF THERAPEUTIC USE

Sunitinib is a small-molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF-1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy.

GENE ASSOCIATION

On the basis of clinical responses for patients with PDGFRB-expressing renal cell carcinoma[90-93] , clear cell sarcoma[97], and solitary fibrous tumor[94-95] , PDGFRB amplification in solid tumors may predict sensitivity to sunitinib.

SUPPORTING DATA

A Phase 2 study of sunitinib in patients with recurrent and refractory ovarian, Fallopian tube, or peritoneal carcinoma reported a modest response rate (partial or complete response) of 8.3% in the 35 enrolled patients[202]. A separate Phase 2 study of sunitinib monotherapy in 30 patients with recurrent epithelial ovarian or primary peritoneal cancer reported one partial response and three CA-125 responses, and stable disease in an additional 16 patients; all responses were seen in patients with platinum-sensitive ovarian cancer, suggesting modest activity of single-agent sunitinib in this tumor type[203].

Talazoparib

Assay findings association

BRCA1
Q1756fs*74

Loss of Heterozygosity score
21.1 %

AREAS OF THERAPEUTIC USE

The PARP inhibitor talazoparib is FDA approved to treat HER2-negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations.

GENE ASSOCIATION

On the basis of strong clinical data in breast cancer[204-206] and additional clinical evidence in ovarian, pancreatic, and prostate cancer[207-209] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors[1-2,174] . In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16%[2,174] .

SUPPORTING DATA

An ORR of 42% (5/12) was reported in patients with BRCA-mutated ovarian cancer treated with talazoparib in a Phase 1 study[208]. In a Phase 2 study of talazoparib in advanced solid tumors, 1 patient with BRIP1-mutated ovarian carcinoma lacking BRCA1/2 alterations experienced a prolonged SD[210].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however the agents listed in this report may have little or no evidence in the patient's tumor type.

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

BIOMARKER

Loss of Heterozygosity score

RESULT

21.1 %

RATIONALE

On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.

NCT03737643

PHASE 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.

TARGETS

VEGFA, PD-L1, PARP

LOCATIONS: California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Barrie (Canada), Sudbury (Canada), Toronto (Canada), Pennsylvania, Montreal (Canada), Rimouski (Canada), Utah, Graz (Austria), Innsbruck (Austria), Linz (Austria), Wien (Austria), Aalst (Belgium), Leuven (Belgium), Namur (Belgium), Oostende (Belgium), Sint-Niklaas (Belgium), Plovdiv (Bulgaria), Sofia (Bulgaria), Varna (Bulgaria), Quebec (Canada), Aalborg (Denmark), Aarhus N (Denmark), Odense C (Denmark), Roskilde (Denmark), Vejle (Denmark), Kuopio (Finland), Oulu (Finland), Turku (Finland), Besançon (France), Bordeaux (France), Marseille (France), Paris (France), Paris Cedex 14 (France), Saint Herblain Cedex (France), Vandoeuvre les Nancy (France), Bad Homburg v.d.H. (Germany), Berlin (Germany), Bielefeld (Germany), Brandenburg (Germany), Dresden (Germany), Düsseldorf (Germany), Essen (Germany), Esslingen am Neckar (Germany), Frankfurt (Germany), Greifswald (Germany), Gütersloh (Germany), Hamburg (Germany), Hannover (Germany), Jena (Germany), Karlsruhe (Germany), Kassel (Germany), Kiel (Germany), Köln (Germany), Leipzig (Germany), Ludwigsburg (Germany), Lübeck (Germany), Mainz (Germany), München (Germany), Offenbach am Main (Germany), Rosenheim (Germany), Rostock (Germany), Saalfeld (Germany), Schweinfurt (Germany), Tübingen (Germany), Ulm (Germany), Worms (Germany), Budapest (Hungary), Debrecen (Hungary), Györ (Hungary), Kaposvár (Hungary), Szeged (Hungary), Zalaegerszeg (Hungary), Brescia (Italy), Lecce (Italy), Milano (Italy), Mirano (Italy), Naples (Italy), Reggio Calabria (Italy), Roma (Italy), Fukuoka-shi (Japan), Kashiwa-shi (Japan), Koto-ku (Japan), Kurume-shi (Japan), Kyoto-shi (Japan), Minato-ku (Japan), Nagoya-shi (Japan), Niigata-shi (Japan), Sapporo-shi (Japan), Sendai-shi (Japan), Shinjuku-ku (Japan), Sunto-gun (Japan), Goyang-si (Korea, Republic of), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Suwon-si (Korea, Republic of), Gdynia (Poland), Szczecin (Poland), Warszawa (Poland), Córdoba (Spain), Madrid (Spain), Terrassa(Barcelona) (Spain), Vigo (Spain), Adana (Turkey), Ankara (Turkey), Istanbul (Turkey), Izmir (Turkey)

NCT03330405

PHASE 2

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

TARGETS

PD-L1, PARP

LOCATIONS: Edmonton (Canada), Arkansas, California, District of Columbia, Obninsk (Russian Federation), Massachusetts, Minnesota, Sydney (Australia), New York, Ohio, Toronto (Canada), Brisbane (Australia), Texas, Murdoch (Australia), Brussels (Belgium), Bruxelles (Belgium), Charleroi (Belgium), Copenhagen (Denmark), Herlev (Denmark), Budapest (Hungary), Miskolc (Hungary), Pecs (Hungary), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Moscow (Russian Federation), Omsk (Russian Federation), Yaroslavl (Russian Federation), Leicester (United Kingdom), London (United Kingdom), Newcastle Upon Tyne (United Kingdom)

NCT03522246

PHASE 3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

TARGETS
PARP, PD-1

LOCATIONS: Albury (Australia), Calgary (Canada), Edmonton (Canada), Arizona, Chaidari (Greece), Abbotsford (Canada), Kelowna (Canada), Surrey (Canada), California, Kashiwa (Japan), Cluj-Napoca (Romania), Colorado, Connecticut, Florida, Georgia, Goyang-si (Korea, Republic of), Seongnam (Korea, Republic of), Seongnam-si (Korea, Republic of), Southampton (United Kingdom), Illinois, Indiana, Iowa, Oradea (Romania), Kawasaki-shi (Japan), Kansas, Canterbury (United Kingdom), Kentucky, Tooting (United Kingdom), Louisiana, Maine, Winnipeg (Canada), Maryland, Massachusetts, Michigan, Northwood (United Kingdom), Minnesota, Missouri, Nevada, New Jersey, New Lambton Heights (Australia), Saint Leonards (Australia), Sydney (Australia), Westmead (Australia), New York, North Carolina, Cliftonville (United Kingdom), Halifax (Canada), Ohio, Oklahoma, Hamilton (Canada), London (Canada), Toronto (Canada), Oregon, Pennsylvania, Montréal (Canada), Sherbrooke (Canada), Brisbane (Australia), Hidaka (Japan), Incheon (Korea, Republic of), Toorak Gardens (Australia), South Dakota, Texas, Utah, Melbourne (Australia), Virginia, Subiaco (Australia), Bebington (United Kingdom), Wisconsin, Leuven (Belgium), Aalborg (Denmark), Odense (Denmark), Kuopio (Finland), Athens (Greece), Patra (Greece), Thessaloniki (Greece), Cork (Ireland), Dublin (Ireland), Limerick (Ireland), Waterford (Ireland), Hadera (Israel), Kfar Saba (Israel), Nahariya (Israel), Ramat Gan (Israel), Safed (Israel), Tel Aviv (Israel), Aviano (Italy), Candiolo (Italy), Catania (Italy), Catanzaro (Italy), Napoli (Italy), Reggio Emilia (Italy), Roma (Italy), Vicenza (Italy), Tokyo (Japan), Seoul (Korea, Republic of), Auckland (New Zealand), Christchurch (New Zealand), Hamilton (New Zealand), Palmerston North (New Zealand), Tauranga (New Zealand), Bialystok (Poland), Białystok (Poland), Gdynia (Poland), Kielce (Poland), Lublin (Poland), Poznań (Poland), Szczecin (Poland), Warszawa (Poland), Brașov (Romania), Bucharest (Romania), Craiova (Romania), Iași (Romania), Suceava (Romania), Timișoara (Romania), Arkhangel'sk (Russian Federation), Kursk (Russian Federation), Omsk (Russian Federation), Pesochnyy (Russian Federation), Pyatigorsk (Russian Federation), Saint Petersburg (Russian Federation), Saransk (Russian Federation), Singapore (Singapore), Barcelona (Spain), Bilbao (Spain), Castillón (Spain), El Palmar (Spain), Jerez de la Frontera (Spain), Madrid (Spain), Oviedo (Spain), Palma De Mallorca (Spain), Santander (Spain), Sevilla (Spain), Kaohsiung (Taiwan), New Taipei City (Taiwan), Taichung (Taiwan), Taipei (Taiwan), Taoyuan (Taiwan), Ankara (Turkey), Manisa (Turkey), Birmingham (United Kingdom), Brighton (United Kingdom), Bristol (United Kingdom), Cambridge (United Kingdom), Dundee (United Kingdom), Edinburgh (United Kingdom), Lancaster (United Kingdom), Leeds (United Kingdom), London (United Kingdom), Manchester (United Kingdom), Oxford (United Kingdom), Poole (United Kingdom), Preston (United Kingdom), Sutton (United Kingdom), Swansea (United Kingdom), Taunton (United Kingdom)

NCT03840200

PHASE 1/2

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

TARGETS
PARP, AKTs

LOCATIONS: California, Roma (Italy), Milano (Italy), Pamplona (Spain), New Jersey, Darlinghurst (Australia), Sydney (Australia), Pennsylvania, Texas, Padova (Italy), Malvern (Australia), Seoul (Korea, Republic of), Barcelona (Spain), Malaga (Spain)

NCT03106987

PHASE 3

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

TARGETS
PARP

LOCATIONS: London (Canada), Montreal (Canada), Leuven (Belgium), Liège (Belgium), Namur (Belgium), Toronto (Canada), Aalborg (Denmark), København Ø (Denmark), Odense C (Denmark), Besançon (France), Bordeaux (France), Caen Cedex 05 (France), Clermont Ferrand cedex 01 (France), Lille (France), Lyon (France), Marseille (France), Montpellier (France), Nantes (France), Nice (France), Paris (France), Paris Cedex 20 (France), Paris Cedex 5 (France), Pierre Benite (France), Plerin SUR MER (France), Saint Herblain (France), Saint-cloud (France), Toulouse Cedex 09 (France), Vandoeuvre-Les-Nancy (France), Berlin (Germany), Dresden (Germany), Essen (Germany), Frankfurt (Germany), Greifswald (Germany), Halle (Germany), Hamburg (Germany), Hannover (Germany), Heidelberg (Germany), Jena (Germany), Köln (Germany), Lübeck (Germany), München (Germany), Regensburg (Germany), Rostock (Germany), Stuttgart (Germany), Ulm (Germany), Wiesbaden (Germany), Haifa (Israel), Holon (Israel), Jerusalem (Israel), Kfar Saba (Israel), Ramat Gan (Israel), Tel-Aviv (Israel), petach Tikva (Israel), Bologna (Italy), Brescia (Italy), Candiolo (Italy), Catania (Italy), Lecce (Italy), Milano (Italy), Modena (Italy), Napoli (Italy), Pisa (Italy), Reggio Emilia (Italy), Roma (Italy), Torino (Italy), Oslo (Norway), Grzepnica (Poland), Krakow (Poland), Lublin (Poland), Olsztyn (Poland), Poznań (Poland), Warszawa (Poland), A Coruña (Spain), Barcelona (Spain), Córdoba (Spain), L'Hospitalet de Llobregat (Spain), Madrid (Spain), Malaga (Spain), Sevilla (Spain), Valencia (Spain), Dundee (United Kingdom), Glasgow (United Kingdom), Leeds (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Taunton (United Kingdom), Wirral (United Kingdom)

NCT03602859

PHASE 3

A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

TARGETS
PD-1, PARP

LOCATIONS: Alaska, Edmonton (Canada), Brasschaat (Belgium), Bordeaux (France), Berlin (Germany), Neumarkt (Germany), Plerin (France), Vancouver (Canada), California, Cluj-Napoca (Romania), Connecticut, Craiova (Romania), Leuven (Belgium), Florida, Hamburg (Germany), Paris (France), Illinois, Montpellier (France), Louisiana, San Sebastián (Spain), Maine, Maryland, Massachusetts, Minnesota, Montana, Wolfsburg (Germany), New Jersey, New York, North Carolina, Ohio, Oklahoma, Hamilton (Canada), London (Canada), Toronto (Canada), Oregon, Cholet Cedex (France), Pennsylvania, Avignon Cedex 9 (France), Montréal (Canada), Sherbrooke (Canada), Rhode Island, Lyon (France), South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Minsk (Belarus), Brussels (Belgium), Praha (Czechia), Praha 8 - Liben (Czechia), Copenhagen (Denmark), Herlev (Denmark), Roskilde (Denmark), Helsinki (Finland), Kuopio (Finland), Tampere (Finland), Turku (Finland), Besancon (France), Caen (France), Clermont-Ferrand (France), Dijon (France), Grenoble (France), La Roche-sur-Yon (France), Le Mans (France), Lille (France), Marseille (France), Mont-de-Marsan (France), Nancy (France), Nantes (France), Nice Cedex 2 (France), Nîmes (France), Paris Cedex 05 (France), Pierre-Bénite (France), Poitiers (France), Reims (France), Saint Priest en Jarez (France), Strasbourg (France), Toulouse Cedex 9 (France), Tours (France), Ravensburg (Germany), Be'er Sheva (Israel), Haifa (Israel), H?olon (Israel), Petach Tikva (Israel), Re?ovot (Israel), Bucuresti (Romania), Constanța (Romania), Timisoara (Romania), Barcelona (Spain), Girona (Spain), Jaen (Spain), Madrid (Spain), Santiago De Compostela (Spain), Toledo (Spain), Valencia (Spain), Zaragoza (Spain), Ávila (Spain), Chernihiv (Ukraine), Lviv (Ukraine), Glasgow (United Kingdom), Portsmouth (United Kingdom), Truro (United Kingdom)

NCT02921919

PHASE 2

Open-Label Extension and Safety Study of Talazoparib

TARGETS
PARP

LOCATIONS: California, Florida, Indiana, Massachusetts, Michigan, Hamilton (Canada), Montreal (Canada), Sutton (United Kingdom), Texas, Marseille cedex 09 (France), Erlangen (Germany), Budapest (Hungary), Warszawa (Poland), Moscow (Russian Federation), Saint-Petersburg (Russian Federation)

NCT03783949

PHASE 2

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

TARGETS
HSP90, PARP

LOCATIONS: Leuven (Belgium), Innsbruck (Austria), Caen (France), Bologna (Italy), Milan (Italy), Rome (Italy)

NCT03695380

PHASE 1

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

TARGETS
PARP, PD-L1, MEK

LOCATIONS: Arizona, California, Napoli (Italy), Florida, Georgia, A Coruna (Spain), Rome (Italy), Milano (Italy), Maryland, Missouri, New York, Oklahoma, Tennessee, Wisconsin, Girona (Spain), Jaen (Spain), Madrid (Spain), Valencia (Spain)

NCT03462212

PHASE 1/2

Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer.

TARGETS
PARP, VEGFA

LOCATIONS: Milan (Italy)

GENE
BRCA1

RATIONALE
BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors.

ALTERATION
Q1756fs*74

NCT03737643

PHASE 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.

TARGETS
VEGFA, PD-L1, PARP

LOCATIONS: California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Barrie (Canada), Sudbury (Canada), Toronto (Canada), Pennsylvania, Montreal (Canada), Rimouski (Canada), Utah, Graz (Austria), Innsbruck (Austria), Linz (Austria), Wien (Austria), Aalst (Belgium), Leuven (Belgium), Namur (Belgium), Oostende (Belgium), Sint-Niklaas (Belgium), Plovdiv (Bulgaria), Sofia (Bulgaria), Varna (Bulgaria), Quebec (Canada), Aalborg (Denmark), Aarhus N (Denmark), Odense C (Denmark), Roskilde (Denmark), Vejle (Denmark), Kuopio (Finland), Oulu (Finland), Turku (Finland), Besançon (France), Bordeaux (France), Marseille (France), Paris (France), Paris Cedex 14 (France), Saint Herblain Cedex (France), Vandoeuvre les Nancy (France), Bad Homburg v.d.H. (Germany), Berlin (Germany), Bielefeld (Germany), Brandenburg (Germany), Dresden (Germany), Düsseldorf (Germany), Essen (Germany), Esslingen am Neckar (Germany), Frankfurt (Germany), Greifswald (Germany), Gütersloh (Germany), Hamburg (Germany), Hannover (Germany), Jena (Germany), Karlsruhe (Germany), Kassel (Germany), Kiel (Germany), Köln (Germany), Leipzig (Germany), Ludwigsburg (Germany), Lübeck (Germany), Mainz (Germany), München (Germany), Offenbach am Main (Germany), Rosenheim (Germany), Rostock (Germany), Saalfeld (Germany), Schweinfurt (Germany), Tübingen (Germany), Ulm (Germany), Worms (Germany), Budapest (Hungary), Debrecen (Hungary), Györ (Hungary), Kaposvár (Hungary), Szeged (Hungary), Zalaegerszeg (Hungary), Brescia (Italy), Lecce (Italy), Milano (Italy), Mirano (Italy), Naples (Italy), Reggio Calabria (Italy), Roma (Italy), Fukuoka-shi (Japan), Kashiwa-shi (Japan), Koto-ku (Japan), Kurume-shi (Japan), Kyoto-shi (Japan), Minato-ku (Japan), Nagoya-shi (Japan), Niigata-shi (Japan), Sapporo-shi (Japan), Sendai-shi (Japan), Shinjuku-ku (Japan), Sunto-gun (Japan), Goyang-si (Korea, Republic of), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Suwon-si (Korea, Republic of), Gdynia (Poland), Szczecin (Poland), Warszawa (Poland), Córdoba (Spain), Madrid (Spain), Terrassa(Barcelona) (Spain), Vigo (Spain), Adana (Turkey), Ankara (Turkey), Istanbul (Turkey), Izmir (Turkey)

NCT03330405

PHASE 2

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

TARGETS
PD-L1, PARP

LOCATIONS: Edmonton (Canada), Arkansas, California, District of Columbia, Obninsk (Russian Federation), Massachusetts, Minnesota, Sydney (Australia), New York, Ohio, Toronto (Canada), Brisbane (Australia), Texas, Murdoch (Australia), Brussels (Belgium), Bruxelles (Belgium), Charleroi (Belgium), Copenhagen (Denmark), Herlev (Denmark), Budapest (Hungary), Miskolc (Hungary), Pecs (Hungary), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Moscow (Russian Federation), Omsk (Russian Federation), Yaroslavl (Russian Federation), Leicester (United Kingdom), London (United Kingdom), Newcastle Upon Tyne (United Kingdom)

NCT03565991

PHASE 2

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

TARGETS
PD-L1, PARP

LOCATIONS: Torette Di Ancona (Italy), California, Kashiwa (Japan), Meldola (Italy), Georgia, Louisiana, Monza (Italy), Milano (Italy), Massachusetts, Missouri, Pamplona (Spain), New Jersey, New York, Amsterdam (Netherlands), Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Chuo-ku (Japan), Rotterdam (Netherlands), Brussel (Belgium), Brussels (Belgium), Edegem (Belgium), Copenhagen (Denmark), Odense C (Denmark), Clermont Ferrand (France), La Rochelle (France), Montpellier Cedex 5 (France), Napoli (Italy), Roma (Italy), Barcelona (Spain), Madrid (Spain), Sevilla (Spain), London (United Kingdom)

NCT03522246

PHASE 3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

TARGETS
PARP, PD-1

LOCATIONS: Albury (Australia), Calgary (Canada), Edmonton (Canada), Arizona, Chaidari (Greece), Abbotsford (Canada), Kelowna (Canada), Surrey (Canada), California, Kashiwa (Japan), Cluj-Napoca (Romania), Colorado, Connecticut, Florida, Georgia, Goyang-si (Korea, Republic of), Seongnam (Korea, Republic of), Seongnam-si (Korea, Republic of), Southampton (United Kingdom), Illinois, Indiana, Iowa, Oradea (Romania), Kawasaki-shi (Japan), Kansas, Canterbury (United Kingdom), Kentucky, Tooting (United Kingdom), Louisiana, Maine, Winnipeg (Canada), Maryland, Massachusetts, Michigan, Northwood (United Kingdom), Minnesota, Missouri, Nevada, New Jersey, New Lambton Heights (Australia), Saint Leonards (Australia), Sydney (Australia), Westmead (Australia), New York, North Carolina, Cliftonville (United Kingdom), Halifax (Canada), Ohio, Oklahoma, Hamilton (Canada), London (Canada), Toronto (Canada), Oregon, Pennsylvania, Montréal (Canada), Sherbrooke (Canada), Brisbane (Australia), Hidaka (Japan), Incheon (Korea, Republic of), Toorak Gardens (Australia), South Dakota, Texas, Utah, Melbourne (Australia), Virginia, Subiaco (Australia), Bebington (United Kingdom), Wisconsin, Leuven (Belgium), Aalborg (Denmark), Odense (Denmark), Kuopio (Finland), Athens (Greece), Patra (Greece), Thessaloniki (Greece), Cork (Ireland), Dublin (Ireland), Limerick (Ireland), Waterford (Ireland), Hadera (Israel), Kfar Saba (Israel), Nahariya (Israel), Ramat Gan (Israel), Safed (Israel), Tel Aviv (Israel), Aviano (Italy), Candiolo (Italy), Catania (Italy), Catanzaro (Italy), Napoli (Italy), Reggio Emilia (Italy), Roma (Italy), Vicenza (Italy), Tokyo (Japan), Seoul (Korea, Republic of), Auckland (New Zealand), Christchurch (New Zealand), Hamilton (New Zealand), Palmerston North (New Zealand), Tauranga (New Zealand), Bialystok (Poland), Białystok (Poland), Gdynia (Poland), Kielce (Poland), Lublin (Poland), Poznań (Poland), Szczecin (Poland), Warszawa (Poland), Brașov (Romania), Bucharest (Romania), Craiova (Romania), Iași (Romania), Suceava (Romania), Timișoara (Romania), Arkhangel'sk (Russian Federation), Kursk (Russian Federation), Omsk (Russian Federation), Pesochnyy (Russian Federation), Pyatigorsk (Russian Federation), Saint Petersburg (Russian Federation), Saransk (Russian Federation), Singapore (Singapore), Barcelona (Spain), Bilbao (Spain), Castillón (Spain), El Palmar (Spain), Jerez de la Frontera (Spain), Madrid (Spain), Oviedo (Spain), Palma De Mallorca (Spain), Santander (Spain), Sevilla (Spain), Kaohsiung (Taiwan), New Taipei City (Taiwan), Taichung (Taiwan), Taipei (Taiwan), Taoyuan (Taiwan), Ankara (Turkey), Manisa (Turkey), Birmingham (United Kingdom), Brighton (United Kingdom), Bristol (United Kingdom), Cambridge (United Kingdom), Dundee (United Kingdom), Edinburgh (United Kingdom), Lancaster (United Kingdom), Leeds (United Kingdom), London (United Kingdom), Manchester (United Kingdom), Oxford (United Kingdom), Poole (United Kingdom), Preston (United Kingdom), Sutton (United Kingdom), Swansea (United Kingdom), Taunton (United Kingdom)

NCT03840200

PHASE 1/2

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

TARGETS
PARP, AKTs

LOCATIONS: California, Roma (Italy), Milano (Italy), Pamplona (Spain), New Jersey, Darlinghurst (Australia), Sydney (Australia), Pennsylvania, Texas, Padova (Italy), Malvern (Australia), Seoul (Korea, Republic of), Barcelona (Spain), Malaga (Spain)

NCT03106987

PHASE 3

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

TARGETS
PARP

LOCATIONS: London (Canada), Montreal (Canada), Leuven (Belgium), Liège (Belgium), Namur (Belgium), Toronto (Canada), Aalborg (Denmark), København Ø (Denmark), Odense C (Denmark), Besançon (France), Bordeaux (France), Caen Cedex 05 (France), Clermont Ferrand cedex 01 (France), Lille (France), Lyon (France), Marseille (France), Montpellier (France), Nantes (France), Nice (France), Paris (France), Paris Cedex 20 (France), Paris Cedex 5 (France), Pierre Benite (France), Plerin SUR MER (France), Saint Herblain (France), Saint-cloud (France), Toulouse Cedex 09 (France), Vandoeuvre-Les-Nancy (France), Berlin (Germany), Dresden (Germany), Essen (Germany), Frankfurt (Germany), Greifswald (Germany), Halle (Germany), Hamburg (Germany), Hannover (Germany), Heidelberg (Germany), Jena (Germany), Köln (Germany), Lübeck (Germany), München (Germany), Regensburg (Germany), Rostock (Germany), Stuttgart (Germany), Ulm (Germany), Wiesbaden (Germany), Haifa (Israel), Holon (Israel), Jerusalem (Israel), Kfar Saba (Israel), Ramat Gan (Israel), Tel-Aviv (Israel), petach Tikva (Israel), Bologna (Italy), Brescia (Italy), Candiolo (Italy), Catania (Italy), Lecce (Italy), Milano (Italy), Modena (Italy), Napoli (Italy), Pisa (Italy), Reggio Emilia (Italy), Roma (Italy), Torino (Italy), Oslo (Norway), Grzepnica (Poland), Krakow (Poland), Lublin (Poland), Olsztyn (Poland), Poznań (Poland), Warszawa (Poland), A Coruña (Spain), Barcelona (Spain), Córdoba (Spain), L'Hospitalet de Llobregat (Spain), Madrid (Spain), Malaga (Spain), Sevilla (Spain), Valencia (Spain), Dundee (United Kingdom), Glasgow (United Kingdom), Leeds (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Taunton (United Kingdom), Wirral (United Kingdom)

NCT03602859

PHASE 3

A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

TARGETS
PD-1, PARP

LOCATIONS: Alaska, Edmonton (Canada), Brasschaat (Belgium), Bordeaux (France), Berlin (Germany), Neumarkt (Germany), Plerin (France), Vancouver (Canada), California, Cluj-Napoca (Romania), Connecticut, Craiova (Romania), Leuven (Belgium), Florida, Hamburg (Germany), Paris (France), Illinois, Montpellier (France), Louisiana, San Sebastián (Spain), Maine, Maryland, Massachusetts, Minnesota, Montana, Wolfsburg (Germany), New Jersey, New York, North Carolina, Ohio, Oklahoma, Hamilton (Canada), London (Canada), Toronto (Canada), Oregon, Cholet Cedex (France), Pennsylvania, Avignon Cedex 9 (France), Montréal (Canada), Sherbrooke (Canada), Rhode Island, Lyon (France), South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Minsk (Belarus), Brussels (Belgium), Praha (Czechia), Praha 8 - Liben (Czechia), Copenhagen (Denmark), Herlev (Denmark), Roskilde (Denmark), Helsinki (Finland), Kuopio (Finland), Tampere (Finland), Turku (Finland), Besancon (France), Caen (France), Clermont-Ferrand (France), Dijon (France), Grenoble (France), La Roche-sur-Yon (France), Le Mans (France), Lille (France), Marseille (France), Mont-de-Marsan (France), Nancy (France), Nantes (France), Nice Cedex 2 (France), Nîmes (France), Paris Cedex 05 (France), Pierre-Bénite (France), Poitiers (France), Reims (France), Saint Priest en Jarez (France), Strasbourg (France), Toulouse Cedex 9 (France), Tours (France), Ravensburg (Germany), Be'er Sheva (Israel), Haifa (Israel), H?olon (Israel), Petach Tikva (Israel), Re?ovot (Israel), Bucuresti (Romania), Constanța (Romania), Timisoara (Romania), Barcelona (Spain), Girona (Spain), Jaen (Spain), Madrid (Spain), Santiago De Compostela (Spain), Toledo (Spain), Valencia (Spain), Zaragoza (Spain), Ávila (Spain), Chernihiv (Ukraine), Lviv (Ukraine), Glasgow (United Kingdom), Portsmouth (United Kingdom), Truro (United Kingdom)

NCT02855944

PHASE 3

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

TARGETS
PARP

LOCATIONS: Calgary (Canada), Fortaleza (Brazil), Colorado, Manchester (United Kingdom), Georgia, Debrecen (Hungary), Brno (Czechia), Ottawa (Canada), Toronto (Canada), Curitiba (Brazil), Praha 5 (Czechia), Montreal (Canada), Montréal (Canada), Sherbrooke (Canada), Ijui (Brazil), Porto Alegre (Brazil), Barretos (Brazil), Florianópolis (Brazil), Sutton (United Kingdom), Grzepnica (Poland), Rio de Janeiro (Brazil), Sao Paulo (Brazil), Ostrava (Czechia), Praha (Czechia), Budapest (Hungary), Haifa (Israel), Holon (Israel), Jerusalem (Israel), Petach-Tikva (Israel), Tel Aviv (Israel), Tel Hashomer (Israel), Bologna (Italy), Candiolo (Italy), Catania (Italy), Milano (Italy), Modena (Italy), Napoli (Italy), Roma (Italy), Bialystok (Poland), Lublin (Poland), Olsztyn (Poland), Poznan (Poland), Szczecin (Poland), Arkhangelsk (Russian Federation), Kursk (Russian Federation), Moscow (Russian Federation), Omsk (Russian Federation), Pyatigorsk (Russian Federation), Ryazan (Russian Federation), Saint Petersburg (Russian Federation), Saint-Petersburg (Russian Federation), Saransk (Russian Federation), Sochi (Russian Federation), Ufa (Russian Federation), Barcelona (Spain), Girona (Spain), La Coruna (Spain), Madrid (Spain), Dnipropetrovsk (Ukraine), Kyiv (Ukraine), Lutsk (Ukraine), Lviv (Ukraine), Odessa (Ukraine), Sumy (Ukraine), Uzhgorod (Ukraine), Cambridge (United Kingdom), Cardiff (United Kingdom), Coventry (United Kingdom), Derby (United Kingdom), Dundee (United Kingdom), Glasgow (United Kingdom), London (United Kingdom), Middlesex (United Kingdom), Newcastle upon Tyne (United Kingdom)

NCT02921919

PHASE 2

Open-Label Extension and Safety Study of Talazoparib

TARGETS
PARP

LOCATIONS: California, Florida, Indiana, Massachusetts, Michigan, Hamilton (Canada), Montreal (Canada), Sutton (United Kingdom), Texas, Marseille cedex 09 (France), Erlangen (Germany), Budapest (Hungary), Warszawa (Poland), Moscow (Russian Federation), Saint-Petersburg (Russian Federation)

NCT03783949

PHASE 2

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

TARGETS
HSP90, PARP

LOCATIONS: Leuven (Belgium), Innsbruck (Austria), Caen (France), Bologna (Italy), Milan (Italy), Rome (Italy)

GENE
PDGFRB

ALTERATION
amplification - equivocal

RATIONALE
PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB-targeted therapies.

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, PDGFRs, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, BRAF, MEK, SMO

LOCATIONS: Vancouver (Canada), Kingston (Canada), London (Canada), Ottawa (Canada), Toronto (Canada), Montreal (Canada), Regina (Canada), Saskatoon (Canada)

NCT02693535

PHASE 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, PDGFRs, RET, mTOR, EGFR, ERBB3, ERBB2, BRAF, MEK, SMO, DDR2, RAF1, PARP, PD-1, CTLA-4, ERBB4

LOCATIONS: Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington

GENE
TP53

ALTERATION
R273C

RATIONALE
TP53 loss of function alterations may predict sensitivity to WEE1 inhibitors. TP53 missense mutations may predict sensitivity to therapies that reactivate mutant p53.

NCT03113487

PHASE 2

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

TARGETS
PD-1, TP53

LOCATIONS: California

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC
R1788H

AR
Q799E

ARID1A
S2179_A2181>R

CASP8
I315V

CSF1R
amplification

EPHB4
P235S

GATA3
amplification

IRS2
Y576C

MSH3
I1082T

NF1
E2203D

NOTCH2
amplification

NSD3 (WHSC1L1)
C770fs*47

NTRK1
G18E

PDCD1 (PD-1)
loss

RICTOR
splice site 393-36_405del49

SDHA
amplification

SPEN
T3451I

WHSC1 (MMSET)
H528N

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes. Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Alterations and Therapies

Biomarker and Genomic Findings

Therapies are ranked based on the following criteria: Therapies with clinical benefit in patient's tumor type (ranked alphabetically within each NCCN category) followed by therapies with clinical benefit in other tumor type (ranked alphabetically within each NCCN category).

Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NCCN Categorization

Biomarker and genomic findings detected may be associated with certain National Comprehensive Cancer Network (NCCN) Compendium drugs or biologics (www.nccn.org). The NCCN categories indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories please refer to the NCCN Compendium.

Limitations

1. The MSI-H/MSS designation by FMI F1CDx test is based on genome wide analysis of 95 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines. The threshold for MSI-H/MSS was determined by analytical concordance to comparator assays (IHC and PCR) using uterine, cecum and colorectal cancer FFPE tissue. The clinical validity of the qualitative MSI designation has not been established. For Microsatellite Instability (MSI) results, confirmatory testing using a validated orthogonal method should be considered.
2. TMB by F1CDx is defined based on counting the total number of all synonymous and nonsynonymous variants present at 5% allele frequency or greater (after filtering) and reported as mutations per megabase (mut/Mb) unit rounded to the nearest integer. The clinical validity of TMB defined by this panel has not been established.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering

effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

PDF Service version: 2.6.0

1. Coleman RL, Oza AM, Lorusso D, et al. ePub Oct 2017 (2017) PMID: 28916367
2. Swisher EM, Lin KK, Oza AM, et al. ePub Jan 2017 (2017) PMID: 27908594
3. Mirza MR, Monk BJ, Herrstedt J, et al. ePub 12 2016 (2016) PMID: 27717299
4. Telli ML, Timms KM, Reid J, et al. 22 (15):3764-73 (2016) PMID: 26957554
5. Timms KM, Abkevich V, Hughes E, et al. ePub Dec 2014 (2014) PMID: 25475740
6. Wang ZC, Birkbak NJ, Culhane AC, et al. 18 (20):5806-15 (2012) PMID: 22912389
7. Telli ML, Jensen KC, Vinayak S, et al. ePub Jun 2015 (2015) PMID: 25847929
8. Isakoff SJ, Mayer EL, He L, et al. ePub Jun 2015 (2015) PMID: 25847936
9. Elvin et al., 2017; ASCO Abstract 5512
10. Abkevich V, Timms KM, Hennessy BT, et al. ePub Nov 2012 (2012) PMID: 23047548
11. Marquard AM, Eklund AC, Joshi T, et al. 3 :9 (2015) PMID: 26015868
12. Pedersen BS, Konstantinopoulos PA, Spillman MA, et al. ePub Sep 2013 (2013) PMID: 23716468
13. Watkins JA, Irshad S, Grigoriadis A, et al. ePub Jun 2014 (2014) PMID: 25093514
14. Vanderstichele A, Busschaert P, Olbrecht S, et al. ePub 11 2017 (2017) PMID: 28950147
15. null ePub Jun 2011 (2011) PMID: 21720365
16. null ePub May 2003 (2003) PMID: 12736286
17. Gatalica Z, Snyder C, Maney T, et al. ePub Dec 2014 (2014) PMID: 25392179
18. Kroemer G, Galluzzi L, Zitvogel L, et al. 4 (7):e1058597 (2015) PMID: 26140250
19. Lal N, Beggs AD, Willcox BE, et al. 4 (3):e976052 (2015) PMID: 25949894
20. Le DT, Uram JN, Wang H, et al. ePub Jun 2015 (2015) PMID: 26028255
21. Ayers et al., 2016; ASCO-SITC Abstract P60
22. Segev Y, Zhang S, Akbari MR, et al. 36 (6):681-4 (2015) PMID: 26775351
23. Plisiecka-Hałasa J, Dansonka-Mieszkowska A, Kraszewska E, et al. 28 (2A):989-96 (null) PMID: 18507046
24. Huang HN, Lin MC, Tseng LH, et al. ePub Mar 2015 (2015) PMID: 25195947
25. Strickland et al., 2016; ASCO Abstract 5514
26. Caliman LP, Tavares RL, Piedade JB, et al. 4 (3):556-560 (2012) PMID: 22970055
27. Aysal A, Karnezis A, Medhi I, et al. ePub Feb 2012 (2012) PMID: 22189970
28. Kocarnik JM, Shiovitz S, Phipps AI 3 (4):269-76 (2015) PMID: 26337942
29. You JF, Buhard O, Ligtenberg MJ, et al. ePub Dec 2010 (2010) PMID: 21081928
30. Bairwa NK, Saha A, Gochhait S, et al. ePub 2014 (2014) PMID: 24623249
31. Boland CR, Thibodeau SN, Hamilton SR, et al. 58 (22):5248-57 (1998) PMID: 9823339
32. Pawlik TM, Raut CP, Rodriguez-Bigas MA 20 (4-5):199-206 (2004) PMID: 15528785
33. Boland CR, Goel A ePub Jun 2010 (2010) PMID: 20420947
34. Samstein RM, Lee CH, Shoushtari AN, et al. ePub 02 2019 (2019) PMID: 30643254
35. Goodman AM, Kato S, Bazhenova L, et al. ePub 11 2017 (2017) PMID: 28835386
36. Goodman AM, Sokol ES, Frampton GM, et al. ePub Oct 2019 (2019) PMID: 31405947
37. Cristescu R, Mogg R, Ayers M, et al. ePub 10 2018 (2018) PMID: 30309915
38. Legrand et al., 2018; ASCO Abstract 12000
39. Chalmers ZR, Connelly CF, Fabrizio D, et al. ePub 04 2017 (2017) PMID: 28420421
40. Strickland KC, Howitt BE, Shukla SA, et al. ePub Mar 2016 (2016) PMID: 26871470
41. Pfeifer GP, You YH, Besaratinia A 571 (1-2):19-31 (2005) PMID: 15748635
42. Hill VK, Gartner JJ, Samuels Y, et al. ePub 2013 (2013) PMID: 23875803
43. Pfeifer GP, Denissenko MF, Olivier M, et al. 21 (48):7435-51 (2002) PMID: 12379884
44. Rizvi NA, Hellmann MD, Snyder A, et al. ePub Apr 2015 (2015) PMID: 25765070
45. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. ePub May 2013 (2013) PMID: 23636398
46. Briggs S, Tomlinson I ePub Jun 2013 (2013) PMID: 23447401
47. Heitzer E, Tomlinson I ePub Feb 2014 (2014) PMID: 24583393
48. null ePub Jul 2012 (2012) PMID: 22810696
49. Roberts SA, Gordenin DA ePub 12 2014 (2014) PMID: 25568919
50. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. ePub Jan 2015 (2015) PMID: 25366685
51. Mateo J, Carreira S, Sandhu S, et al. ePub Oct 2015 (2015) PMID: 26510020
52. Tutt A, Robson M, Garber JE, et al. ePub Jul 2010 (2010) PMID: 20609467
53. Robson M, Im SA, Senkus E, et al. ePub 08 2017 (2017) PMID: 28578601
54. Sandhu SK, Schelman WR, Wilding G, et al. ePub Aug 2013 (2013) PMID: 23810788
55. Drew Y, Ledermann J, Hall G, et al. ePub Mar 2016 (2016) PMID: 27002934
56. Pujade-Lauraine E, Ledermann JA, Selle F, et al. ePub Sep 2017 (2017) PMID: 28754483
57. Ledermann JA, Harter P, Gourley C, et al. ePub Nov 2016 (2016) PMID: 27617661
58. Fong PC, Boss DS, Yap TA, et al. ePub Jul 2009 (2009) PMID: 19553641
59. Audeh MW, Carmichael J, Penson RT, et al. ePub Jul 2010 (2010) PMID: 20609468
60. Fong PC, Yap TA, Boss DS, et al. ePub May 2010 (2010) PMID: 20406929
61. Gelmon KA, Tischkowitz M, Mackay H, et al. ePub Sep 2011 (2011) PMID: 21862407
62. Kaye SB, Lubinski J, Matulonis U, et al. ePub Feb 2012 (2012) PMID: 22203755
63. Domchek SM, Aghajanian C, Shapira-Frommer R, et al. ePub Feb 2016 (2016) PMID: 26723501
64. Moore K, Colombo N, Scambia G, et al. ePub Oct 2018 (2018) PMID: 30345884
65. Coleman RL, Fleming GF, Brady MF, et al. ePub Sep 2019 (2019) PMID: 31562800
66. Do K, Wilsker D, Ji J, et al. ePub Oct 2015 (2015) PMID: 25964244
67. Rzepecka IK, Szafron L, Stys A, et al. 205 (3):94-100 (2012) PMID: 22469508
68. McAlpine JN, Porter H, Köbel M, et al. ePub May 2012 (2012) PMID: 22282309
69. Wang YQ, Yan Q, Zhang JR, et al. ePub Feb 2013 (2013) PMID: 23006047
70. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. ePub Jan 2008 (2008) PMID: 18165636
71. Bolton KL, Chenevix-Trench G, Goh C, et al. ePub Jan 2012 (2012) PMID: 22274685
72. McLaughlin JR, Rosen B, Moody J, et al. ePub Jan 2013 (2013) PMID: 23257159
73. Verhaak RG, Tamayo P, Yang JY, et al. ePub Jan 2013 (2013) PMID: 23257362
74. Safra T, Lai WC, Borgato L, et al. ePub Nov 2013 (2013) PMID: 24131973
75. Romero I, Bast RC ePub Apr 2012 (2012) PMID: 22416079
76. O'Donovan PJ, Livingston DM ePub Jun 2010 (2010) PMID: 20400477
77. Nelson AC, Holt JT ePub Jul 2010 (2010) PMID: 20681793
78. Silver DP, Livingston DM ePub Aug 2012 (2012) PMID: 22843421
79. Ludwig T, Fisher P, Ganesan S, et al. 15 (10):1188-93 (2001) PMID: 11358863
80. Miki Y, Swensen J, Shattuck-Eidens D, et al. 266 (5182):66-71 (1994) PMID: 7545954
81. Wooster R, Bignell G, Lancaster J, et al. 378 (6559):789-92 (null) PMID: 8524414
82. Ford D, Easton DF, Bishop DT, et al. 343 (8899):692-5 (1994) PMID: 7907678
83. null ePub Jun 2005 (2005) PMID: 16369438
84. Whittemore AS, Gong G, Itnyre J 60 (3):496-504 (1997) PMID: 9042908
85. Claus EB, Schildkraut JM, Thompson WD, et al. 77 (11):2318-24 (1996) PMID: 8635102
86. Struewing JP, Hartge P, Wacholder S, et al. 336 (20):1401-8 (1997) PMID: 9145676
87. Oddoux C, Struewing JP, Clayton CM, et al. 14 (2):188-90 (1996) PMID: 8841192
88. King MC, Marks JH, Mandell JB, et al. ePub Oct 2003 (2003) PMID: 14576434
89. Hall MJ, Reid JE, Burbidge LA, et al. 115 (10):2222-33 (2009) PMID: 19241424
90. Ornstein et al., 2015; ASCO GU Abstract 450
91. Dornbusch J, Zacharis A, Meinhardt M, et al. ePub 2013 (2013) PMID: 24086736
92. Garcia-Donas J, Leandro-García LJ, González Del Alba A, et al. ePub Sep 2013 (2013) PMID: 23788753
93. Ma X, Wang L, Li H, et al. ePub 08 2016 (2016) PMID: 27488093
94. Stacchiotti S, Negri T, Palassini E, et al. ePub May 2010 (2010) PMID: 20457621
95. Stacchiotti S, Negri T, Libertini M, et al. ePub Dec 2012 (2012) PMID: 22711763
96. Shah CH, Viktorsson K, Sherif A, et al. ePub Jul 2013 (2013) PMID: 23542751
97. Stacchiotti S, Grosso F, Negri T, et al. ePub May 2010 (2010) PMID: 20093352
98. Kobayashi K, Miyagawa N, Mitsui K, et al. ePub Jun 2015 (2015) PMID: 25400122
99. Lengline E, Beldjord K, Dombret H, et al. ePub Nov 2013 (2013) PMID: 24186319
100. Roberts KG, Li Y, Payne-Turner D, et al. ePub Sep 2014 (2014) PMID: 25207766
101. Weston BW, Hayden MA, Roberts KG, et al. ePub Sep 2013 (2013) PMID: 23835704
102. Chang et al., 2016; DOI 10.1016/j.jcrpr.2015.10.003
103. Li Z, Yang R, Zhao J, et al. ePub Mar 2011 (2011) PMID: 21072821

104. Metzgeroth G, Walz C, Erben P, et al. ePub Dec 2008 (2008) PMID: 18950453

105. Apperley JF, Gardembas M, Melo JV, et al. ePub Aug 2002 (2002) PMID: 12181402

106. Cornfield D, Shah U, Cross N, et al. ePub Mar 2012 (2012) PMID: 22331939

107. David M, Cross NC, Burgstaller S, et al. 109 (1):61-4 (2007) PMID: 16960151

108. Walz C, Metzgeroth G, Haferlach C, et al. ePub Feb 2007 (2007) PMID: 17296564

109. Winkelmann N, Hidalgo-Curtis C, Waghorn K, et al. ePub Jul 2013 (2013) PMID: 23186533

110. Apte SM, Bucana CD, Killion JJ, et al. 93 (1):78-86 (2004) PMID: 15047217

111. Schmandt RE, Broaddus R, Lu KH, et al. 98 (4):758-64 (2003) PMID: 12910520

112. Roberts KG, Morin RD, Zhang J, et al. ePub Aug 2012 (2012) PMID: 22897847

113. Chmielecki J, Peifer M, Viale A, et al. ePub Jan 2012 (2012) PMID: 21938754

114. Vizmanos JL, Novo FJ, Román JP, et al. 64 (8):2673-6 (2004) PMID: 15087377

115. Kobayashi K, Mitsui K, Ichikawa H, et al. ePub Jun 2014 (2014) PMID: 24628626

116. Tsao AS, Wei W, Kuhn E, et al. ePub Nov 2011 (2011) PMID: 21729646

117. Hirai H, Arai T, Okada M, et al. ePub Apr 2010 (2010) PMID: 20107315

118. Bridges KA, Hirai H, Buser CA, et al. 17 (17):5638-48 (2011) PMID: 21799033

119. Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. 17 (9):2799-806 (2011) PMID: 21389100

120. Osman AA, Monroe MM, Ortega Alves MV, et al. ePub Feb 2015 (2015) PMID: 25504633

121. Xu L, Huang CC, Huang W, et al. 1 (5):337-46 (2002) PMID: 12489850

122. Xu L, Tang WH, Huang CC, et al. 7 (10):723-34 (2001) PMID: 11713371

123. Camp ER, Wang C, Little EC, et al. ePub Apr 2013 (2013) PMID: 23470564

124. Kim SS, Rait A, Kim E, et al. ePub Feb 2015 (2015) PMID: 25240597

125. Pirollo KF, Nemunaitis J, Leung PK, et al. ePub Sep 2016 (2016) PMID: 27357628

126. Hajdenberg et al., 2012; ASCO Abstract e15010

127. Lehmann S, Bykov VJ, Ali D, et al. ePub Oct 2012 (2012) PMID: 22965953

128. Mohell N, Alfredsson J, Fransson Å, et al. ePub Jun 2015 (2015) PMID: 26086967

129. Fransson Å, Glaessgen D, Alfredsson J, et al. ePub May 2016 (2016) PMID: 27179933

130. Gourley et al., 2016; ASCO Abstract 5571

131. Leijen S, van Geel RM, Pavlick AC, et al. ePub Dec 2016 (2016) PMID: 27601554

132. Moore et al., 2019; ASCO Abstract 5513

133. Leijen S, van Geel RM, Sonke GS, et al. ePub 12 2016 (2016) PMID: 27998224

134. Oza et al., 2015; ASCO Abstract 5506

135. Méndez E, Rodriguez CP, Kao MC, et al. 24 (12):2740-2748 (2018) PMID: 29535125

136. Ma CX, Cai S, Li S, et al. ePub Apr 2012 (2012) PMID: 22446188

137. Ahmed AA, Etemadmoghadam D, Temple J, et al. ePub May 2010 (2010) PMID: 20229506

138. Wojnarowicz PM, Oros KK, Quinn MC, et al. ePub 2012 (2012) PMID: 23029043

139. Kuhn E, Kurman RJ, Vang R, et al. ePub Feb 2012 (2012) PMID: 21990067

140. Karst AM, Drapkin R 2010 :932371 (2010) PMID: 19746182

141. Gadducci A, Guerrieri ME, Genazzani AR ePub Aug 2012 (2012) PMID: 22304686

142. Rechsteiner M, Zimmermann AK, Wild PJ, et al. ePub Oct 2013 (2013) PMID: 23965232

143. Okamoto A, Sameshima Y, Yokoyama S, et al. 51 (19):5171-6 (1991) PMID: 1680546

144. McDaniel AS, Stall JN, Hovelson DH, et al. ePub Nov 2015 (2015) PMID: 26181193

145. Kindelberger DW, Lee Y, Miron A, et al. 31 (2):161-9 (2007) PMID: 17255760

146. Meserve EEK, Brouwer J, Crum CP ePub May 2017 (2017) PMID: 28106106

147. Kurman RJ, Shih IeM ePub Jul 2011 (2011) PMID: 21683865

148. Altman AD, Nelson GS, Ghatage P, et al. ePub Sep 2013 (2013) PMID: 23558569

149. Giurgea LN, Ungureanu C, Mihailovici MS 53 (4):967-73 (2012) PMID: 23303020

150. Rajesh NG, Rekha K, Krishna B 50 (2):284-7 (2007) PMID: 17883046

151. de Graeff P, Crijns AP, de Jong S, et al. ePub Jul 2009 (2009) PMID: 19513073

152. Brown CJ, Lain S, Verma CS, et al. ePub Dec 2009 (2009) PMID: 19935675

153. Joerger AC, Fersht AR 77 :557-82 (2008) PMID: 18410249

154. Kato S, Han SY, Liu W, et al. 100 (14):8424-9 (2003) PMID: 12826609

155. Kamada R, Nomura T, Anderson CW, et al. ePub Jan 2011 (2011) PMID: 20978130

156. Bougeard G, Renaux-Petel M, Flaman JM, et al. ePub Jul 2015 (2015) PMID: 26014290

157. Sorrell AD, Espenschied CR, Culver JO, et al. ePub Feb 2013 (2013) PMID: 23355100

158. Nichols KE, Malkin D, Garber JE, et al. 10 (2):83-7 (2001) PMID: 11219776

159. Taubert H, Meye A, Würl P 4 (6):365-72 (1998) PMID: 10780879

160. Kleihues P, Schäuble B, zur Hausen A, et al. 150 (1):1-13 (1997) PMID: 9006316

161. Gonzalez KD, Noltner KA, Buzin CH, et al. ePub Mar 2009 (2009) PMID: 19204208

162. Lalloo F, Varley J, Ellis D, et al. 361 (9363):1101-2 (2003) PMID: 12672316

163. null ePub Sep 2012 (2012) PMID: 22960745

164. Chattopadhyay I, Singh A, Phukan R, et al. 696 (2):130-8 (2010) PMID: 20083228

165. Li H, Du Y, Zhang D, et al. ePub Jul 2012 (2012) PMID: 22552777

166. Dmitriev AA, Rosenberg EE, Krasnov GS, et al. ePub 2015 (2015) PMID: 26491211

167. Carvalho RH, Hou J, Haberle V, et al. ePub May 2013 (2013) PMID: 23524404

168. Trimarchi MP, Yan P, Groden J, et al. ePub 2017 (2017) PMID: 28278225

169. Gebhard C, Schwarzfischer L, Pham TH, et al. 66 (12):6118-28 (2006) PMID: 16778185

170. Volkomorov V, Grigoryeva E, Krasnov G, et al. 35 (1):2-7 (2013) PMID: 23528308

171. Iddawelda et al., 2009; ASCO Abstract 574

172. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 93 (18):9850-7 (1996) PMID: 8790420

173. Konstantinopolous et al., 2018; ASCO Abstract 106

174. Coleman et al., 2016; ASCO Abstract 5540

175. González-Martín A, Pothuri B, Vergote I, et al. ePub Sep 2019 (2019) PMID: 31562799

176. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. ePub Jun 2019 (2019) PMID: 31194228

177. Mirza et al., 2016; ASCO Abstract 5555

178. Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. ePub Oct 2019 (2019) PMID: 31474354

179. Del Conte G, Sessa C, von Moos R, et al. ePub Aug 2014 (2014) PMID: 25025963

180. Matulonis UA, Penson RT, Domchek SM, et al. ePub 06 2016 (2016) PMID: 26961146

181. Ledermann J, Harter P, Gourley C, et al. ePub Apr 2012 (2012) PMID: 22452356

182. Ledermann J, Harter P, Gourley C, et al. ePub Jul 2014 (2014) PMID: 24882434

183. Oza AM, Cibula D, Benzaquen AO, et al. ePub Jan 2015 (2015) PMID: 25481791

184. Liu JF, Barry WT, Birrer M, et al. ePub Oct 2014 (2014) PMID: 25218906

185. Barber LJ, Sandhu S, Chen L, et al. ePub Feb 2013 (2013) PMID: 23165508

186. Norquist B, Wurz KA, Pennil CC, et al. ePub Aug 2011 (2011) PMID: 21709188

187. Sakai W, Swisher EM, Jacquemont C, et al. ePub Aug 2009 (2009) PMID: 19654294

188. Rytelewski M, Maleki Vareki S, Mangala LS, et al. ePub Apr 2016 (2016) PMID: 26959114

189. Quigley D, Alumkal JJ, Wyatt AW, et al. ePub 09 2017 (2017) PMID: 28450426

190. Gornstein EL, Sandefur S, Chung JH, et al. ePub 04 2018 (2018) PMID: 29325860

191. Kristeleit et al., 2014; ASCO Abstract 2573

192. Domcheck et al., 2016; ASCO Abstract 4110

193. Oza AM, Tinker AV, Oaknin A, et al. ePub 11 2017 (2017) PMID: 28882436

194. Kristeleit R, Shapiro GI, Burris HA, et al. 23 (15):4095-4106 (2017) PMID: 28264872

195. Herzog TJ, Scambia G, Kim BG, et al. ePub Jul 2013 (2013) PMID: 23591401

196. Matei D, Sill MW, Lankes HA, et al. ePub Jan 2011 (2011) PMID: 21098323

197. Bodnar L, Górnas M, Szczylik C ePub Oct 2011 (2011) PMID: 21723597

198. Hainsworth JD, Thompson DS, Bismayer JA, et al. ePub May 2015 (2015) PMID: 25556916

199. Schwandt A, von Gruenigen VE, Wenham RM, et al. ePub Aug 2014 (2014) PMID: 24619298

200. Sehouli et al., 2016; ASCO Abstract 5522

201. Koshiyama M, Matsumura N, Baba T, et al. ePub Jan 2014 (2014) PMID: 24096267

202. Campos SM, Penson RT, Matulonis U, et al. ePub Feb 2013 (2013) PMID: 22885865

203. Biagi JJ, Oza AM, Chalchal HI, et al. ePub Feb 2011 (2011) PMID: 20705911

204. Turner et al., 2017; ASCO Abstract 1007

205. Litton JK, Rugo HS, Ettl J, et al. ePub Aug 2018 (2018) PMID: 30110579

206. Ettl J, Quek RGW, Lee KH, et al. ePub Sep 2018 (2018) PMID: 30124753

207. Meehan et al., 2017; AACR Abstract 4687

208. de Bono J, Ramanathan RK, Mina L, et al. ePub 06 2017 (2017) PMID: 28242752

209. Lu E, Thomas GV, Chen Y, et al. ePub 08 2018 (2018) PMID: 30099369

210. Piha Paul et al., 2018; AACR abstract A096